Logo

Indications - Dexmedetomidine Hydrochloride Injection is a central alpha-2 adrenergic agonist indicated for sedation of non-intubated patients prior to and/or during surgical and other procedures

Dosage & Administration - Dilute in 0.9% Sodium Chloride Injection to concentration of 4 mcg/mL prior to administration. To be administered only by health care providers skilled in the management of patients in the operating room setting. Administer intravenously using a controlled infusion device. Administration duration should not exceed 24 hours. Continuously monitor blood pressure, heart rate, and oxygen levels during administration and as clinically appropriate after discontinuation. Initiation of Procedural Sedation: More invasive procedures or awake fiberoptic intubation: 1 mcg/kg over 10 minutes Less invasive procedures such as ophthalmic surgery: 0.5 mcg/kg over 10 minutes Maintenance of Procedural Sedation All procedures except awake fiberoptic intubation: Generally, initiate at 0.6 mcg/kg/hour and titrate to achieve desired clinical effect with dosages ranging from 0.2 to 1 mcg/kg/hour. Awake fiberoptic intubation: Administer 0.7 mcg/kg/hour until the endotracheal tube is secured

Side Effects - The most common adverse reactions (incidence greater than 10%) were hypotension, respiratory depression, and bradycardia.

Contraindications - None

Others - Pregnancy & Lactation Pregnancy: There are no studies conducted with dexmedetomidine hydrochloride in pregnant women to inform any drug-associated risks. Lactation: There is no information regarding the presence of dexmedetomidine hydrochloride in human milk, the effects of the drug on the breastfed infant, or the effects of the drug on milk production.